{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T16:42:23Z","timestamp":1743266543166},"reference-count":51,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2020]]},"DOI":"10.3960\/jslrt.20002","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T22:04:49Z","timestamp":1589321089000},"page":"130-137","source":"Crossref","is-referenced-by-count":4,"title":["Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies"],"prefix":"10.3960","volume":"60","author":[{"given":"Kensuke","family":"Kojima","sequence":"first","affiliation":[{"name":"Department of Hematology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan A.","family":"Burger","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Bosch F, Dalla-Favera R. Chronic lymphocytic leukaemia: from genetics to treatment. Nat Rev Clin Oncol. 2019; 16: 684-701.","DOI":"10.1038\/s41571-019-0239-8"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Burger JA, O\u2019Brien S. Evolution of CLL treatment\u2014 from chemoimmunotherapy to targeted and individualized therapy. Nat Rev Clin Oncol. 2018; 15: 510-527.","DOI":"10.1038\/s41571-018-0037-8"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol. 2019; 94: 1266-1287.","DOI":"10.1002\/ajh.25595"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Sharman JP, Banerji V, Fogliatto LM, <i>et al<\/i>. ELEVATE TN: Phase 3 study of acalabrutinib combined with obinutuzumab (O) or alone vs O plus chlorambucil (Clb) in patients (Pts) with treatment-naive chronic lymphocytic leukemia (CLL). Blood. 2019; 134(Supplement_1): 31.","DOI":"10.1182\/blood-2019-128404"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Sharman JP, Coutre SE, Furman RR <i>et al.<\/i> Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. J Clin Oncol. 2019; 37: 1391-1402.","DOI":"10.1200\/JCO.18.01460"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Flinn IW, Hillmen P, Montillo M <i>et al.<\/i> The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL. Blood. 2018; 132: 2446-2455.","DOI":"10.1182\/blood-2018-05-850461"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Goede V, Fischer K, Busch R <i>et al.<\/i> Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014; 370: 1101-1110.","DOI":"10.1056\/NEJMoa1313984"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Rai KR, Sawitsky A, Cronkite EP <i>et al.<\/i> Clinical staging of chronic lymphocytic leukemia. Blood. 1975; 46: 219-234.","DOI":"10.1182\/blood.V46.2.219.219"},{"key":"9","unstructured":"9 Binet JL, Leporrier M, Dighiero G <i>et al.<\/i> A clinical staging system for chronic lymphocytic leukemia.Prognostic significance. Cancer. 1977; 40: 855-864."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Dighiero G, Maloum K, Desablens B <i>et al.<\/i>. Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med. 1998; 338: 1506-1514.","DOI":"10.1056\/NEJM199805213382104"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Hallek M, Cheson BD, Catovsky D <i>et al.<\/i> iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018; 131: 2745-2760.","DOI":"10.1182\/blood-2017-09-806398"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Hallek M, Fischer K, Fingerle-Rowson G <i>et al.<\/i>. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010; 376: 1164-1174.","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Fischer K, Cramer P, Busch R <i>et al.<\/i> Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012; 30: 3209-3216.","DOI":"10.1200\/JCO.2011.39.2688"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Leeksma AC, Taylor J, Wu B <i>et al.<\/i> Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia. Leukemia. 2019; 33: 390-402.","DOI":"10.1038\/s41375-018-0215-9"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 . An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016; 17: 779-790.","DOI":"10.1016\/S1470-2045(16)30029-8"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Eichhorst B, Fink AM, Bahlo J <i>et al.<\/i>. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016; 17: 928-942.","DOI":"10.1016\/S1470-2045(16)30051-1"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Thompson PA, Tam CS, O\u2019Brien SM <i>et al.<\/i> Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016; 127: 303-309.","DOI":"10.1182\/blood-2015-09-667675"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Strati P, Keating MJ, O\u2019Brien SM <i>et al.<\/i> Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood. 2014; 123: 3727-3732.","DOI":"10.1182\/blood-2013-11-538116"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Shanafelt TD, Wang XV, Kay NE <i>et al.<\/i> Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019; 381: 432-443.","DOI":"10.1056\/NEJMoa1817073"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Woyach JA, Ruppert AS, Heerema NA <i>et al.<\/i> Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018; 379: 2517-2528.","DOI":"10.1056\/NEJMoa1812836"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Burger JA, Barr PM, Robak T <i>et al.<\/i> Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020; 34: 787-798.","DOI":"10.1038\/s41375-019-0602-x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Moreno C, Greil R, Demirkan F <i>et al.<\/i> Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019; 20: 43-56.","DOI":"10.1016\/S1470-2045(18)30788-5"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Seymour JF, Kipps TJ, Eichhorst B <i>et al.<\/i> Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018; 378: 1107-1120.","DOI":"10.1056\/NEJMoa1713976"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Seymour JF, Kipps TJ, Eichhorst BF, <i>et al<\/i>. Four-year analysis of Murano study confirms sustained benefit of time-limited venetoclax-rituximab (VenR) in relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL). Blood. 2019; 134(Supplement_1): 355.","DOI":"10.1182\/blood-2019-123930"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Byrd JC, Furman RR, Coutre SE <i>et al.<\/i> Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013; 369: 32-42.","DOI":"10.1056\/NEJMoa1215637"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 O\u2019Brien S, Hillmen P, Coutre S <i>et al.<\/i> Safety analysis of four randomized controlled studies of ibrutinib in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma or mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2018; 18: 648-657.e15.","DOI":"10.1016\/j.clml.2018.06.016"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Wiczer TE, Levine LB, Brumbaugh J <i>et al.<\/i> Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Adv. 2017; 1: 1739-1748.","DOI":"10.1182\/bloodadvances.2017009720"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Ahn IE, Underbayev C, Albitar A <i>et al.<\/i> Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood. 2017; 129: 1469-1479.","DOI":"10.1182\/blood-2016-06-719294"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Burger JA, Landau DA, Taylor-Weiner A <i>et al.<\/i> Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016; 7: 11589.","DOI":"10.1038\/ncomms11589"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Shanafelt TD, Wang V, Kay NE, <i>et al<\/i>. Ibrutinib and rituximab provides superior clinical outcome compared to FCR in younger patients with chronic lymphocytic leukemia (CLL): Extended follow-up from the E1912 trial. Blood. 2019; 134(Supplement_1): 33.","DOI":"10.1182\/blood-2019-126824"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Kojima K, Konopleva M, Samudio IJ <i>et al.<\/i> Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML. Cell Cycle. 2006; 5: 2778-2786.","DOI":"10.4161\/cc.5.23.3520"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Kojima K, Duvvuri S, Ruvolo V <i>et al.<\/i> Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737. Cancer. 2012; 118: 1023-1031.","DOI":"10.1002\/cncr.26360"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Kojima K, Konopleva M, McQueen T <i>et al.<\/i> Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood. 2006; 108: 993-1000.","DOI":"10.1182\/blood-2005-12-5148"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Fischer K, Ritgen M, Al-Sawaf O, <i>et al<\/i>. Quantitative analysis of minimal residual disease (MRD) shows high rates of undetectable MRD after fixed-duration chemotherapy-free treatment and serves as surrogate marker for progression-free survival: A prospective analysis of the randomized CLL14 trial. Blood. 2019; 134(Supplement_1): 36.","DOI":"10.1182\/blood-2019-125825"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Fischer K, Al-Sawaf O, Bahlo J <i>et al.<\/i> Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019; 380: 2225-2236.","DOI":"10.1056\/NEJMoa1815281"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Roberts AW, Ma S, Kipps TJ <i>et al.<\/i> Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood. 2019; 134: 111-122.","DOI":"10.1182\/blood.2018882555"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Blombery P, Anderson MA, Gong J <i>et al.<\/i> Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 2019; 9: 342-353.","DOI":"10.1158\/2159-8290.CD-18-1119"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Herling CD, Abedpour N, Weiss J <i>et al.<\/i> Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. Nat Commun. 2018; 9: 727.","DOI":"10.1038\/s41467-018-03170-7"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Gui\u00e8ze R, Liu VM, Rosebrock D <i>et al.<\/i> Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies. Cancer Cell. 2019; 36: 369-384.e13.","DOI":"10.1016\/j.ccell.2019.08.005"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Molica S, Giannarelli D, Shanafelt TD. Comparison of venetoclax plus rituximab with B-cell receptor inhibitors in patients with relapsed\/refractory chronic lymphocytic leukemia: a systematic review and network Meta-analysis. Leuk Lymphoma. 2020; 61: 955-958.","DOI":"10.1080\/10428194.2019.1691193"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Cuneo A, Follows G, Rigolin GM <i>et al.<\/i>. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. Haematologica. 2018; 103: 1209-1217.","DOI":"10.3324\/haematol.2018.189837"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Rossi D, Spina V, Gaidano G. Biology and treatment of Richter syndrome. Blood. 2018; 131: 2761-2772.","DOI":"10.1182\/blood-2018-01-791376"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Cwynarski K, van Biezen A, de Wreede L <i>et al.<\/i> Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter\u2019s syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012; 30: 2211-2217.","DOI":"10.1200\/JCO.2011.37.4108"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Parikh SA, Habermann TM, Chaffee KG <i>et al.<\/i> Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma. Am J Hematol. 2015; 90: 334-338.","DOI":"10.1002\/ajh.23939"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Hampel PJ, Larson MC, Kabat B <i>et al.<\/i> Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre. Br J Haematol. 2018; 183: 421-427.","DOI":"10.1111\/bjh.15545"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 O\u2019Brien S, Furman RR, Coutre S <i>et al.<\/i> Single-agent ibrutinib in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018; 131: 1910-1919.","DOI":"10.1182\/blood-2017-10-810044"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Byrd JC, Hillmen P, O\u2019Brien S <i>et al.<\/i> Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019; 133: 2031-2042.","DOI":"10.1182\/blood-2018-08-870238"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Jones JA, Mato AR, Wierda WG <i>et al.<\/i> Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018; 19: 65-75.","DOI":"10.1016\/S1470-2045(17)30909-9"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 O\u2019Brien S, Jones JA, Coutre SE <i>et al.<\/i> Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016; 17: 1409-1418.","DOI":"10.1016\/S1470-2045(16)30212-1"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 Stilgenbauer S, Eichhorst B, Schetelig J <i>et al.<\/i> Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2018; 36: 1973-1980.","DOI":"10.1200\/JCO.2017.76.6840"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51 Nakamura N, Kuze T, Hashimoto Y <i>et al.<\/i> Analysis of the immunoglobulin heavy chain gene variable region of 101 cases with peripheral B cell neoplasms and B cell chronic lymphocytic leukemia in the Japanese population. Pathol Int. 1999; 49: 595-600.","DOI":"10.1046\/j.1440-1827.1999.00911.x"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/60\/4\/60_20002\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,19]],"date-time":"2020-12-19T04:32:16Z","timestamp":1608352336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/60\/4\/60_20002\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.20002","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}